Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07612254 · ClinicalTrials.gov registry record · Phase 1
aPBI Re-irradiation
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07612254: Clinical Trial Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT07612254 is a Phase 1 study that has not yet begun recruiting, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07612254, a Phase 1 study, has not yet begun recruiting, sponsored by Dartmouth-Hitchcock Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is to determine whether acute treatment-associated adverse events following breast re-irradiation with aPBI are acceptably low and to assess local control following breast re-irradiation with aPBI. An exploratory aim is to assess cosmetic outcomes following breast re-irradiation with aPBI.
Primary Outcome
Acceptably low acute treatment-associated adverse events following breast re-irradiation with aPBI.
Interventions
- RADIATION Reirradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06-03 |
| Est. Completion | 2033-04 |
| Phase | Phase 1 |
What is known before NCT07612254 opens enrollment
NCT07612254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which Reirradiation is the first listed.
NCT07612254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07612254 about?
NCT07612254 is a clinical study titled "aPBI Re-irradiation". This study is to determine whether acute treatment-associated adverse events following breast re-irradiation with aPBI are acceptably low and to assess local control following breast re-irradiation with aPBI. An exploratory aim is to assess cosmetic outcomes following breast re-irradiation with aPBI...
What is the current status of trial NCT07612254?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-06-03. Estimated completion is 2033-04.
What interventions are being tested in trial NCT07612254?
The interventions under investigation include: Reirradiation (RADIATION).
Who is sponsoring clinical trial NCT07612254?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07612254's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI